Podcasts

Episode 11 | Optimising Diagnosis & Treatment Pathways For Lung Cancer Patients

In this episode we discuss how delays in diagnosis are one of the main factors associated with reduced survival rates and how we can improve these for lung cancer patients in Australia.

Optimising Diagnosis & Treatment Pathways For Lung Cancer Patients

Episode Summary

Delays in diagnosis are one of the main factors associated with reduced survival rates for lung cancer patients. In this TOGA Podcast, we will discuss some of the challenges associated with treatment delay and how we can improve these for lung cancer patients in Australia. Dr Malinda Itchins, Prof Wendy Cooper and A/Prof Phillip Antippa join us in the conversation. Clinical guidelines have been implemented in some countries to standardize the diagnosis process, better define the time from diagnosis to the beginning of treatment, and to improve clinical results in lung cancer. In Australia, periods of 14 days from the initial referral of the GP to the first specialty consultation, and also from diagnosis to the first treatment are recommended. However, previous reviews showed an average time of 27 days for lung cancer diagnosis, with time distributions below those recommended by international guidelines (ranging from 6 to 45 days). Across all three modalities, a treatment delay of four weeks is associated with an increase in the risk of death.

 

Thank you to Novartis for sponsoring this TOGA Podcast.

 

Reference:
ASPiRATION is an observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. Find more information here: https://thoraciconcology.org.au/aspiration/

Show Hosts

This episode’s host are:

  • Dr Malinda Itchins, Thoracic Medical Oncologist, Royal North Shore Hospital, GenesisCare and North Shore Private
  • Prof Wendy Cooper, Pathologist, Royal Prince Alfred Hospital, NSW Health Pathology
  • A/Prof Phillip Antippa, Philanthropy Chair, TOGA; Cardiothoracic Surgeon and Head of Thoracic Surgical Services at The Royal Melbourne Hospital and the Peter MacCallum Cancer Centre

Play Episode 11 | Optimising Diagnosis & Treatment Pathways For Lung Cancer Patients

More Podcasts

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer
In this Podcast, Mark Scott talks with Alexandra Golledge about her challenges in diagnosis, searching for the best treatments available, living in a regional area
Prof Nick Pavlakis and Prof Emily Stone join discuss the remarkable advances in screening, diagnosing and treating lung cancer that occurred during 2020.
Dorothy Keefe, CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients.
A fireside chat with Prunella Blinman, Shankar Siva and our three Preceptees: Anna Lawless, Abhijit Pal and Melanie Rabbets about their experiences, their learnings, what
In this episode, Prof Anna Nowak and A/Prof Steven Kao discuss the emerging treatments for mesothelioma patients and the DREAM3R trial.